A304360 Stock Overview
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
S.Biomedics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩34,450.00 |
| 52 Week High | ₩51,600.00 |
| 52 Week Low | ₩6,950.00 |
| Beta | 0 |
| 11 Month Change | -11.44% |
| 3 Month Change | 4.24% |
| 1 Year Change | 292.82% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 82.95% |
Recent News & Updates
Shareholder Returns
| A304360 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -11.2% | 4.1% | -2.6% |
| 1Y | 292.8% | 37.5% | 2.2% |
Return vs Industry: A304360 exceeded the KR Biotechs industry which returned 36.7% over the past year.
Return vs Market: A304360 exceeded the KR Market which returned 2.2% over the past year.
Price Volatility
| A304360 volatility | |
|---|---|
| A304360 Average Weekly Movement | 17.3% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A304360's share price has been volatile over the past 3 months.
Volatility Over Time: A304360's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 54 | n/a | www.sbiomedics.com |
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound. The company provides testing services; and owns platform technologies for developing cell therapy products.
S.Biomedics Co., Ltd. Fundamentals Summary
| A304360 fundamental statistics | |
|---|---|
| Market cap | ₩395.30b |
| Earnings (TTM) | -₩7.36b |
| Revenue (TTM) | ₩12.70b |
31.1x
P/S Ratio-53.7x
P/E RatioIs A304360 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A304360 income statement (TTM) | |
|---|---|
| Revenue | ₩12.70b |
| Cost of Revenue | ₩6.27b |
| Gross Profit | ₩6.43b |
| Other Expenses | ₩13.79b |
| Earnings | -₩7.36b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -641.20 |
| Gross Margin | 50.64% |
| Net Profit Margin | -57.94% |
| Debt/Equity Ratio | 103.3% |
How did A304360 perform over the long term?
See historical performance and comparison